ViroGates A/S (CPH:VIRO)

Market Cap	103.03M +54.9%
Revenue (ttm)	8.90M +24.7%
Net Income	-10.40M
EPS	-1.32
Shares Out	9.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	870
Open	11.20
Previous Close	11.10
Day's Range	11.20 - 11.20
52-Week Range	5.98 - 17.40
Beta	0.73
RSI	47.46
Earnings Date	Mar 26, 2026

About ViroGates

ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company’s product includes suPARnostic TurbiLatex, a latex particle-enhan...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2000
• Employees: 7
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: VIRO

Financial Performance

In 2025, ViroGates's revenue was 8.90 million, an increase of 24.67% compared to the previous year's 7.14 million. Losses were -10.40 million, -27.52% less than in 2024.